This Einstein-Mount Sinai Diabetes Research Center (ES-DRC) supports the discovery, application and translation of scientific knowledge for the treatment and cure of diabetes. Building upon the established successes of Einstein's Diabetes Research and Training Center (DRTC) and the Icahn School of Medicine at Mount Sinai's Diabetes and Obesity Metabolism Institute (DOMI), the ES-DRC serves as a nexus to i) enhance diabetes research, education and training; ii) attract, mentor and retain research investigators; iii) provide state- of-the-art Core services to maximize research productivity; iv) foster interdisciplinary collaborations locally and regionally, and v) promote the translation of scientific findings from the bench to the bedside and ultimately the community, especially in underserved and minority populations. To accomplish these goals, we reorganized the ES-DRC into five cutting-edge biomedical cores spanning the basic, pre-clinical, and clinical research `translational' divide: 1) Animal Physiology; 2) Stable Isotope & Metabolomics; 3) Human Islet & Adenovirus; 4) Biomarker & Analytical Research; and 5) Translational Research Cores. At the molecular, cellular, tissue, animal based integrated physiology levels, we provide the infrastructure to investigate the basic mechanisms of type 1 and type 2 diabetes. These investigations are translated into human based clinical investigation, population based studies that include large cohort studies of under-represented minorities, women and HIV infected individuals. To attain these goals, we use the support of an Administrative Core for which its personnel have overall responsibility for management, integration and promotion of research and training among Einstein, Mount Sinai and our affiliated institutional Center members. This Core also provides support for our highly successful Pilot & Feasibility Study Program, Enrichment activities and coordination between the Einstein and Mount Sinai Clinical Translational Science Awards (CTSA). This infrastructure already allowed us to establish several new innovative programs including a new microgrant initiative, and establishment of a laboratory information management system (LMIS) for ordering, billing, monitoring experimental progress, data acquisition, data analyses and data distribution to investigators. In parallel, the ES-DRC research cores provide robust cutting-edge methodologies and equipment necessary to identify the molecular mechanisms responsible for the development of diabetes in model organisms and in human-based studies that can be translated to clinical care.

Public Health Relevance

Diabetes and related metabolic disorders are rapidly increasing and have major impacts on both the quality of life and the lifespan of the US population, and are therefore responsible for a large portion of our health care cost burden. The goals of this project are to provide resources for molecular, cellular, tissue, organismal, pre- clinical, clinical and translation research to improve and diabetes treatment and reduce its cost.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK020541-41
Application #
9272874
Study Section
Special Emphasis Panel (ZDK1-GRB-S (J4)P)
Program Officer
Hyde, James F
Project Start
1996-12-01
Project End
2020-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
41
Fiscal Year
2017
Total Cost
$1,888,937
Indirect Cost
$606,994
Name
Albert Einstein College of Medicine, Inc
Department
Type
Domestic Higher Education
DUNS #
079783367
City
Bronx
State
NY
Country
United States
Zip Code
10461
Shu, Jun; Santulli, Gaetano (2018) Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis 275:379-381
Karakose, Esra; Ackeifi, Courtney; Wang, Peng et al. (2018) Advances in drug discovery for human beta cell regeneration. Diabetologia :
Zhao, Xiaoping; Zhao, Li; Yang, Hao et al. (2018) Pyruvate kinase M2 interacts with nuclear sterol regulatory element-binding protein 1a and thereby activates lipogenesis and cell proliferation in hepatocellular carcinoma. J Biol Chem 293:6623-6634
Toledo, Miriam; Batista-Gonzalez, Ana; Merheb, Emilio et al. (2018) Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1. Cell Metab 28:268-281.e4
Walker, Elizabeth A; Weiss, Linda; Gary-Webb, Tiffany L et al. (2018) Power Up for Health: Pilot Study Outcomes of a Diabetes Prevention Program for Men from Disadvantaged Neighborhoods. Am J Mens Health 12:989-997
Sharma, Yogeshwar; Liu, Jinghua; Kristian, Kathleen E et al. (2018) In Atp7b-/- Mice Modeling Wilson's Disease Liver Repopulation with Bone Marrowderived Myofibroblasts or Inflammatory Cells and not Hepatocytes is Deleterious. Gene Expr :
Stepankova, Martina; Bartonkova, Iveta; Jiskrova, Eva et al. (2018) Methylindoles and Methoxyindoles are Agonists and Antagonists of Human Aryl Hydrocarbon Receptor. Mol Pharmacol 93:631-644
Kane, N S; Hoogendoorn, C J; Tanenbaum, M L et al. (2018) Physical symptom complaints, cognitive emotion regulation strategies, self-compassion and diabetes distress among adults with Type 2 diabetes. Diabet Med 35:1671-1677
Ackeifi, Courtney A; Swartz, Ethan A; Wang, Peng (2018) Cell-Based Methods to Identify Inducers of Human Pancreatic Beta-Cell Proliferation. Methods Mol Biol 1787:87-100
Walters, Ryan O; Arias, Esperanza; Diaz, Antonio et al. (2018) Sarcosine Is Uniquely Modulated by Aging and Dietary Restriction in Rodents and Humans. Cell Rep 25:663-676.e6

Showing the most recent 10 out of 533 publications